Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy, a targeted treatment for selective tumor ablation. The company is headquartered in Israel, with a presence in Luxembourg, France, and USA, as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel. ImPact Biotech holds exclusive rights from the Weizmann Institute of S...
ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy, a targeted treatment for selective tumor ablation. The company is headquartered in Israel, with a presence in Luxembourg, France, and USA, as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel. ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.

List your booth number for exhibitions, ask us